FDA: CAR T-Cell Therapies May Increase Risk for Rare Secondary Cancers

Citing recent indications that CAR T-cell therapy may cause rare secondary cancers, the U.S. Food and Drug Administration has told pharmaceutical companies to add a boxed warning to their products.

However, FDA spokesperson Carly Kempler told NBC News that despite the new warning, “the overall benefits of these products continue to outweigh their potential risks.” Twenty-five reports of rare blood cancers in patients who had received CAR T-cell therapy prompted the agency to add the boxed warning, Kempler said.

Source: Advances and More licensed by HealthDay

https://advancesandmore.com/advances_article.htm?id=NDU1NDJkNjktNTFmYS00ZGU5LTkwMDYtNGIzMWQ3OTA1ZjE0&client=Nw%3D%3D&section=undefined